Top-Rated StocksTop-RatedNASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $58.97 -0.79 (-1.32%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$58.98 +0.01 (+0.02%) As of 08/1/2025 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Disc Medicine Stock (NASDAQ:IRON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Disc Medicine alerts:Sign Up Key Stats Today's Range$58.01▼$60.0150-Day Range$45.12▼$60.9452-Week Range$30.82▼$68.73Volume373,398 shsAverage Volume331,135 shsMarket Capitalization$2.04 billionP/E RatioN/ADividend YieldN/APrice Target$95.73Consensus RatingBuy Company Overview Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. Read More Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks73rd Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 73% of companies evaluated by MarketBeat, and ranked 286th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDisc Medicine has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDisc Medicine has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -15.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 3.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted13.44% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Disc Medicine has recently decreased by 7.82%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.44% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Disc Medicine has recently decreased by 7.82%, indicating that investor sentiment is improving significantly. News and Social Media3.9 / 5News Sentiment1.01 News SentimentDisc Medicine has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Disc Medicine this week, compared to 6 articles on an average week.Search Interest8 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Disc Medicine to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,315,908.00 in company stock.Percentage Held by InsidersOnly 4.24% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Email Address IRON Stock News HeadlinesDisc Medicine, Inc. (NASDAQ:IRON) Director Sells $518,351.68 in StockAugust 2 at 6:57 AM | insidertrades.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 13,033 Shares of StockJuly 26, 2025 | insidertrades.comTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.August 2 at 2:00 AM | Porter & Company (Ad)Insider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 664 Shares of StockJuly 23, 2025 | insidertrades.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) CFO Sells 2,031 Shares of StockJuly 19, 2025 | insidertrades.comDisc Medicine, Inc. (IRON) Set to Submit NDA for Bitopertin in October 2025July 28, 2025 | finance.yahoo.comBrokerages Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $95.73July 26, 2025 | americanbankingnews.comRaymond James Reaffirms Their Buy Rating on Disc Medicine (IRON)July 20, 2025 | theglobeandmail.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $63.40 on January 1st, 2025. Since then, IRON stock has decreased by 7.0% and is now trading at $58.97. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) announced its earnings results on Wednesday, May, 7th. The company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.99) by $0.03. Who are Disc Medicine's major shareholders? Top institutional investors of Disc Medicine include TD Asset Management Inc (0.15%), Aberdeen Group plc (0.09%), Atle Fund Management AB (0.07%) and Y Intercept Hong Kong Ltd (0.03%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Kevin Bitterman, Mona Ashiya, John D Quisel, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Brian Richard Macdonald, Joanne Bryce and William Richard White. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings5/07/2025Today8/02/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Disc Medicine$95.73 High Price Target$132.00 Low Price Target$75.00 Potential Upside/Downside+62.3%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-22.61% Return on Assets-21.07% Debt Debt-to-Equity Ratio0.04 Current Ratio37.65 Quick Ratio37.65 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$14.85 per share Price / Book3.97Miscellaneous Outstanding Shares34,634,000Free Float33,166,000Market Cap$2.04 billion OptionableNot Optionable Beta0.76 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:IRON) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredMicrosoft's Next Big Bet?Microsoft just broke ground on a revolutionary power system that could deliver virtually limitless, carbon-fre...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.